EDGAR Filing Documents for 0001193125-14-407879

Form 8-K - Current report:

SEC Accession No. 0001193125-14-407879

Filing Date

2014-11-12

Accepted

2014-11-12 08:01:00

Documents

Period of Report

2014-11-07

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d816446d8k.htm	8-K	24864
2	EX-10.2	d816446dex102.htm	EX-10.2	26959
3	EX-99.1	d816446dex991.htm	EX-99.1	72645
4	GRAPHIC	g816446im1.jpg	GRAPHIC	8434
	Complete submission text file	0001193125-14-407879.txt		137765

Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421

Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904

Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)